Primary Sclerosing Cholangitis– Pipeline Insight, 2020
This report can be delivered to the clients within 48 - 72 Hours
DelveInsight’s, “Primary Sclerosing Cholangitis– Pipeline Insight, 2020,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Primary Sclerosing Cholangitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Primary Sclerosing Cholangitis: Overview
Primary sclerosing cholangitis (PSC) is characterized by inflammation in the bile ducts (cholangitis) that leads to scarring (sclerosis), narrowing of the ducts, and a buildup of bile in the liver. Early signs and symptoms include extreme tiredness, abdominal pain, and itchiness. As the condition worsens it may cause jaundice, an enlarged spleen, and eventually liver cirrhosis and failure. Other complications may include weight loss, vitamin deficiency, and osteoporosis. Many people with PSC develop other autoimmune conditions such as inflammatory bowel disease, type 1 diabetes, celiac disease, or thyroid disease. PSC is also a risk factor for cancer of the bile ducts (cholangiocarcinoma).
Symptoms
Symptoms of PSC include:
A diagnosis of primary sclerosing cholangitis is made based upon a thorough clinical evaluation, a detailed patient history, identification of characteristic findings, and a variety of specialized tests.
Treatment
There is no specific, universal treatment for individuals with PSC. Treatment is directed toward the specific symptoms that are apparent in each individual and at slowing the progression of the disorder. Endoscopic surgery to remove blockages and enlarge narrowed bile ducts may be of benefit to help prevent liver deterioration in certain cases. Lost vitamins should be replaced when required to prevent complications related to these deficiencies. Antibiotics may be useful in controlling inflammation or infection. Individuals with PSC are encouraged to follow a normal healthy diet and to avoid alcohol or only have alcohol in small amounts.
Primary Sclerosing Cholangitis Emerging Drugs Chapters
This segment of the Primary Sclerosing Cholangitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Primary Sclerosing Cholangitis Emerging Drugs
Further product details are provided in the report.
Primary Sclerosing Cholangitis: Therapeutic Assessment
This segment of the report provides insights about the different Primary Sclerosing Cholangitis drugs segregated based on following parameters that define the scope of the report, such as:
Primary Sclerosing Cholangitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Primary Sclerosing Cholangitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Primary Sclerosing Cholangitis drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Primary Sclerosing Cholangitis– Pipeline Insight, 2020,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Primary Sclerosing Cholangitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Primary Sclerosing Cholangitis: Overview
Primary sclerosing cholangitis (PSC) is characterized by inflammation in the bile ducts (cholangitis) that leads to scarring (sclerosis), narrowing of the ducts, and a buildup of bile in the liver. Early signs and symptoms include extreme tiredness, abdominal pain, and itchiness. As the condition worsens it may cause jaundice, an enlarged spleen, and eventually liver cirrhosis and failure. Other complications may include weight loss, vitamin deficiency, and osteoporosis. Many people with PSC develop other autoimmune conditions such as inflammatory bowel disease, type 1 diabetes, celiac disease, or thyroid disease. PSC is also a risk factor for cancer of the bile ducts (cholangiocarcinoma).
Symptoms
Symptoms of PSC include:
- Itchy skin.
- Extreme tiredness (fatigue)
- Belly pain.
- Yellowing of the skin and eyes, called jaundice.
- Chills and fever from infection of bile ducts
A diagnosis of primary sclerosing cholangitis is made based upon a thorough clinical evaluation, a detailed patient history, identification of characteristic findings, and a variety of specialized tests.
Treatment
There is no specific, universal treatment for individuals with PSC. Treatment is directed toward the specific symptoms that are apparent in each individual and at slowing the progression of the disorder. Endoscopic surgery to remove blockages and enlarge narrowed bile ducts may be of benefit to help prevent liver deterioration in certain cases. Lost vitamins should be replaced when required to prevent complications related to these deficiencies. Antibiotics may be useful in controlling inflammation or infection. Individuals with PSC are encouraged to follow a normal healthy diet and to avoid alcohol or only have alcohol in small amounts.
Primary Sclerosing Cholangitis Emerging Drugs Chapters
This segment of the Primary Sclerosing Cholangitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Primary Sclerosing Cholangitis Emerging Drugs
- Cenicriviroc: Tobira Therapeutics
- IMU-838: Immunic
Further product details are provided in the report.
Primary Sclerosing Cholangitis: Therapeutic Assessment
This segment of the report provides insights about the different Primary Sclerosing Cholangitis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Primary Sclerosing Cholangitis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Primary Sclerosing Cholangitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Primary Sclerosing Cholangitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Primary Sclerosing Cholangitis drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Primary Sclerosing Cholangitis R&D. The therapies under development are focused on novel approaches to treat/improve Primary Sclerosing Cholangitis.
- In November 2018, Gilead Sciences announced that treatment with GS-9674, an investigational, selective, nonsteroidal farnesoid X receptor (FXR) agonist, led to significant improvements in liver biochemistry and markers of cholestasis in patients with primary sclerosing cholangitis (PSC). Data were presented at The Liver Meeting 2018 in San Francisco.
- Primary Sclerosing Cholangitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Primary Sclerosing Cholangitis drugs?
- How many Primary Sclerosing Cholangitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Primary Sclerosing Cholangitis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Primary Sclerosing Cholangitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Primary Sclerosing Cholangitis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Biotie Therapies
- Tobira Therapeutics, Inc.
- Pliant Therapeutics, Inc.
- NGM Biopharmaceuticals, Inc
- Mirum Pharmaceuticals, Inc.
- Genentech, Inc.
- EuroPharma
- Intercept Pharmaceuticals
- HighTide Biopharma Pty Ltd
- Gilead Sciences
- Dr. Falk Pharma GmbH
- BTT1023
- Cenicriviroc
- PLN-7480
- NGM282
- LUM001
- Erlotinib (Tarceva)
- Curcumin
- OCA
- HTD1801
- Cilofexor
- Simtuzuma
- norUDCA
Introduction
Executive Summary
Primary Sclerosing Cholangitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Primary Sclerosing Cholangitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Primary Sclerosing Cholangitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Primary Sclerosing Cholangitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Cilofexor - Gilead Sciences/Phenex Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Cenicriviroc - Tobira Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
PLN 74809: Pliant Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
MORF 627: Morphic Therapeutic
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Primary Sclerosing Cholangitis Key Companies
Primary Sclerosing Cholangitis Key Products
Primary Sclerosing Cholangitis- Unmet Needs
Primary Sclerosing Cholangitis- Market Drivers and Barriers
Primary Sclerosing Cholangitis- Future Perspectives and Conclusion
Primary Sclerosing Cholangitis Analyst Views
Primary Sclerosing Cholangitis Key Companies
Appendix
Executive Summary
Primary Sclerosing Cholangitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Primary Sclerosing Cholangitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Primary Sclerosing Cholangitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Primary Sclerosing Cholangitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Cilofexor - Gilead Sciences/Phenex Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Cenicriviroc - Tobira Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
PLN 74809: Pliant Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
MORF 627: Morphic Therapeutic
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Primary Sclerosing Cholangitis Key Companies
Primary Sclerosing Cholangitis Key Products
Primary Sclerosing Cholangitis- Unmet Needs
Primary Sclerosing Cholangitis- Market Drivers and Barriers
Primary Sclerosing Cholangitis- Future Perspectives and Conclusion
Primary Sclerosing Cholangitis Analyst Views
Primary Sclerosing Cholangitis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Primary Sclerosing Cholangitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Primary Sclerosing Cholangitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Primary Sclerosing Cholangitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Primary Sclerosing Cholangitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
